[Immunoprevention of HPV-Associated Neoplasias].

Autor: Gross GE; Bahhofstraße 81, 29559, Wrestedt-Stederdorf, Deutschland. gerd.e.gross@t-online.de.

Publikováno v: MMW Fortschritte der Medizin [MMW Fortschr Med] 2022 May; Vol. 164 (10), pp. 56-60.

German evidence and consensus-based (S3) guideline: Vaccination recommendations for the prevention of HPV-associated lesions.

Autor: Gross GE; Department of Dermatology and Venereology, University Hospital Rostock, Rostock, Germany.; Paul Ehrlich Society for Chemotherapy, HPV Management Forum, Germany., Werner RN; Department of Dermatology, Venereology and Allergology, Division of Evidence Based Medicine in Dermatology (dEBM), Charité - University Medical Center Berlin, corporate member of Free University Berlin, Humboldt University Berlin, and Berlin Institute of Health, Berlin, Germany., Avila Valle GL; Department of Dermatology, Venereology and Allergology, Division of Evidence Based Medicine in Dermatology (dEBM), Charité - University Medical Center Berlin, corporate member of Free University Berlin, Humboldt University Berlin, and Berlin Institute of Health, Berlin, Germany., Bickel M; Infektiologikum Frankfurt, Frankfurt am Main, Germany., Brockmeyer NH; Department of Dermatology, Venereology and Allergology, Ruhr University Bochum, Center for Sexual Health - WIR 'Walk In Ruhr', Bochum, Germany., Doubek K; Gynecology Office Dr. Klaus Doubek, Wiesbaden, Germany., Gallwas J; Department of Gynecology and Obstetrics, Georg August University Göttingen, Göttingen, Germany., Gieseking F; Gynecology Office Heussweg, Hamburg, Germany., Haase H; Women Support Group Cancer - Federal Association, Germany., Hillemanns P; Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany., Ikenberg H; MVZ for Cytology and Molecular Biology (CytoMol), Frankfurt am Main, Germany., Jongen J; Proctology Office Kiel, Kiel, Germany., Kaufmann AM; Department of Gynecology, Campus Virchow Hospital, Charité - University Medical Center Berlin, corporate member of Free University Berlin, Humboldt University Berlin and Berlin Institute of Health, Berlin, Germany., Klußmann JP; Department of Otorhinolaryngology, Head and Neck Surgery, -University Hospital of Cologne, Medical Faculty, University of Cologne, Cologne, Germany., von Knebel Doeberitz M; Department of Applied Tumor Biology, Institute of Pathology, University Hospital Heidelberg, Clinical Cooperation Unit G105 of the German Cancer Research Center (DKFZ), Heidelberg, Germany., Knuf M; Hospital for Child and Adolescent Health, Helios Dr. Horst Schmidt Kliniken, Wiesbaden, Germany.; Pediatric Infectiology, University Medical Center Mainz, Mainz, Germany., Köllges R; Office for Child and Adolescent Health, Mönchengladbach, Germany., Laws HJ; Department of Pediatric Oncology, Hematology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany., Mikolajczyk R; Institute of Medical Epidemiology, Biometry and Informatics (IMEBI), Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany., Neis KJ; Gynecology Office am Staden, Saarbrücken, Germany., Petry KU; Gynecology Clinic, Hospital Wolfsburg, Wolfsburg, Germany., Pfister H; Institute of Virology, University of Cologne, Cologne, Germany., Schlaeger M; Office Dr. Martin Schlaeger, Oldenburg, Germany., Schneede P; Urology Clinic, Hospital Memmingen, Memmingen, Germany., Schneider A; MVZ in Fürstenberg-Karree, Berlin, Germany., Smola S; Institute of Virology, Saarland University Medical Center, Medical Faculty, Saarland University, Homburg/Saar, Germany., Tiews S; MVZ Laboratory for Cytopathology Dr. Steinberg GmbH, Soest, Germany., Nast A; Department of Dermatology, Venereology and Allergology, Division of Evidence Based Medicine in Dermatology (dEBM), Charité - University Medical Center Berlin, corporate member of Free University Berlin, Humboldt University Berlin, and Berlin Institute of Health, Berlin, Germany., Gaskins M; Department of Dermatology, Venereology and Allergology, Division of Evidence Based Medicine in Dermatology (dEBM), Charité - University Medical Center Berlin, corporate member of Free University Berlin, Humboldt University Berlin, and Berlin Institute of Health, Berlin, Germany., Wieland U; National Reference Center for Papilloma and Polyoma Viruses, Institute of Virology, University Hospital of Cologne, University of Cologne, Cologne, Germany.

Publikováno v: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG [J Dtsch Dermatol Ges] 2021 Mar; Vol. 19 (3), pp. 479-494. Date of Electronic Publication: 2021 Feb 26.

S2k guidelines for the diagnosis and treatment of herpes zoster and postherpetic neuralgia.

Autor: Gross GE; Department of Dermatology and Venereology, Rostock University Medical Center, Rostock, Germany., Eisert L; Charité - University Medicine Berlin, Corporate Member of Free University of Berlin, Humboldt University of Berlin, and Berlin Institute of Health, Department of Dermatology, Venereology und Allergy, Division of Evidence-based Medicine (dEBM), Berlin, Germany., Doerr HW; Institute of Medical Virology, University Medical Center Frankfurt, Frankfurt (Main), Germany., Fickenscher H; Institute for Infectious Diseases, Christian Albrecht University and Schleswig-Holstein University Medical Center, Kiel, Germany., Knuf M; Dr. Horst Schmidt Hospital for Pediatric and Adolescent Medicine (Helios Kliniken), Wiesbaden, Germany., Maier P; Department of Ophthalmology, Freiburg University Medical Center, Freiburg, Germany., Maschke M; Department of Neurology, Neurophysiology and Early Neurological Rehabilitation, Krankenhaus der Barmherzigen Brüder (Merciful Brothers' Hospital), Trier, Germany., Müller R; Department of Otorhinolaryngology, Medical Faculty of the Carl Gustav Carus Technical University of Dresden, Dresden, Germany., Pleyer U; Department of Ophthalmology, Charité - University Medicine Berlin, Berlin, Germany., Schäfer M; Department of Anesthesiology and Surgical Intensive Care, Charité - University Medicine Berlin, Berlin, Germany., Sunderkötter C; Department of Dermatology and Venereology, Halle University Medical Center, Halle (Saale), Germany., Werner RN; Charité - University Medicine Berlin, Corporate Member of Free University of Berlin, Humboldt University of Berlin, and Berlin Institute of Health, Department of Dermatology, Venereology und Allergy, Division of Evidence-based Medicine (dEBM), Berlin, Germany., Wutzler P; Department of Virology, Jena University Medical Center, Friedrich Schiller University, Jena, Germany., Nast A; Charité - University Medicine Berlin, Corporate Member of Free University of Berlin, Humboldt University of Berlin, and Berlin Institute of Health, Department of Dermatology, Venereology und Allergy, Division of Evidence-based Medicine (dEBM), Berlin, Germany.

Publikováno v: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG [J Dtsch Dermatol Ges] 2020 Jan; Vol. 18 (1), pp. 55-78. Date of Electronic Publication: 2020 Jan 17.

Central nervous system pediatric multi-disciplinary tumor board: a single center experience.

Autor: Russo, Rosellina¹ (AUTHOR) rosellina.russo@policlinicogemelli.it, Verdolotti, Tommaso¹ (AUTHOR), Perna, Alessandro¹ (AUTHOR), Ruscelli, Luigi¹ (AUTHOR), D'Abronzo, Rosa¹ (AUTHOR), Romano, Alberto¹ (AUTHOR), Ferrara, Giuseppe¹ (AUTHOR), Parisi, Davide¹ (AUTHOR), Infante, Amato¹ (AUTHOR), Chiesa, Silvia¹ (AUTHOR), Massimi, Luca^2,3 (AUTHOR), Tamburrini, Gianpiero^2,3 (AUTHOR), Ruggiero, Antonio^3,4 (AUTHOR), Gessi, Marco^3,5 (AUTHOR), Martucci, Matia¹ (AUTHOR), Gaudino, Simona^1,3 (AUTHOR)

Publikováno v: BMC Cancer. 9/13/2024, Vol. 24 Issue 1, p1-7. 7p.

Endothelial Cell-Targeted Deletion of PPAR γ Blocks Rosiglitazone-Induced Plasma Volume Expansion and Vascular Remodeling in Adipose Tissue.

Autor: Akiyama TE; Cardiometabolic Disorders Department, Merck Research Laboratories, Kenilworth, New Jersey (T.E.A., L.A.M., N.S., E.I.Z., H.L., J.W.W., C.H.C., J.P.B.); Department of Pathology and Molecular Medicine (G.E.S.-G., E.D.L., C.J.B.N.), Cancer Biology and Genetics Division, Cancer Research Institute (R.E.R., C.J.B.N.), and Department of Biomedical and Molecular Sciences (J.Y.S., C.J.B.N.), Queen's University, Kingston, Ontario, Canada; National Cancer Institute, National Institutes of Health, Bethesda, Maryland (F.J.G.); and Takeda Pharmaceuticals International, Inc., Cambridge, Massachusetts (J.P.B.)., Skelhorne-Gross GE; Cardiometabolic Disorders Department, Merck Research Laboratories, Kenilworth, New Jersey (T.E.A., L.A.M., N.S., E.I.Z., H.L., J.W.W., C.H.C., J.P.B.); Department of Pathology and Molecular Medicine (G.E.S.-G., E.D.L., C.J.B.N.), Cancer Biology and Genetics Division, Cancer Research Institute (R.E.R., C.J.B.N.), and Department of Biomedical and Molecular Sciences (J.Y.S., C.J.B.N.), Queen's University, Kingston, Ontario, Canada; National Cancer Institute, National Institutes of Health, Bethesda, Maryland (F.J.G.); and Takeda Pharmaceuticals International, Inc., Cambridge, Massachusetts (J.P.B.)., Lightbody ED; Cardiometabolic Disorders Department, Merck Research Laboratories, Kenilworth, New Jersey (T.E.A., L.A.M., N.S., E.I.Z., H.L., J.W.W., C.H.C., J.P.B.); Department of Pathology and Molecular Medicine (G.E.S.-G., E.D.L., C.J.B.N.), Cancer Biology and Genetics Division, Cancer Research Institute (R.E.R., C.J.B.N.), and Department of Biomedical and Molecular Sciences (J.Y.S., C.J.B.N.), Queen's University, Kingston, Ontario, Canada; National Cancer Institute, National Institutes of Health, Bethesda, Maryland (F.J.G.); and Takeda Pharmaceuticals International, Inc., Cambridge, Massachusetts (J.P.B.)., Rubino RE; Cardiometabolic Disorders Department, Merck Research Laboratories, Kenilworth, New Jersey (T.E.A., L.A.M., N.S., E.I.Z., H.L., J.W.W., C.H.C., J.P.B.); Department of Pathology and Molecular Medicine (G.E.S.-G., E.D.L., C.J.B.N.), Cancer Biology and Genetics Division, Cancer Research Institute (R.E.R., C.J.B.N.), and Department of Biomedical and Molecular Sciences (J.Y.S., C.J.B.N.), Queen's University, Kingston, Ontario, Canada; National Cancer Institute, National Institutes of Health, Bethesda, Maryland (F.J.G.); and Takeda Pharmaceuticals International, Inc., Cambridge, Massachusetts (J.P.B.)., Shi JY; Cardiometabolic Disorders Department, Merck Research Laboratories, Kenilworth, New Jersey (T.E.A., L.A.M., N.S., E.I.Z., H.L., J.W.W., C.H.C., J.P.B.); Department of Pathology and Molecular Medicine (G.E.S.-G., E.D.L., C.J.B.N.), Cancer Biology and Genetics Division, Cancer Research Institute (R.E.R., C.J.B.N.), and Department of Biomedical and Molecular Sciences (J.Y.S., C.J.B.N.), Queen's University, Kingston, Ontario, Canada; National Cancer Institute, National Institutes of Health, Bethesda, Maryland (F.J.G.); and Takeda Pharmaceuticals International, Inc., Cambridge, Massachusetts (J.P.B.)., McNamara LA; Cardiometabolic Disorders Department, Merck Research Laboratories, Kenilworth, New Jersey (T.E.A., L.A.M., N.S., E.I.Z., H.L., J.W.W., C.H.C., J.P.B.); Department of Pathology and Molecular Medicine (G.E.S.-G., E.D.L., C.J.B.N.), Cancer Biology and Genetics Division, Cancer Research Institute (R.E.R., C.J.B.N.), and Department of Biomedical and Molecular Sciences (J.Y.S., C.J.B.N.), Queen's University, Kingston, Ontario, Canada; National Cancer Institute, National Institutes of Health, Bethesda, Maryland (F.J.G.); and Takeda Pharmaceuticals International, Inc., Cambridge, Massachusetts (J.P.B.)., Sharma N; Cardiometabolic Disorders Department, Merck Research Laboratories, Kenilworth, New Jersey (T.E.A., L.A.M., N.S., E.I.Z., H.L., J.W.W., C.H.C., J.P.B.); Department of Pathology and Molecular Medicine (G.E.S.-G., E.D.L., C.J.B.N.), Cancer Biology and Genetics Division, Cancer Research Institute (R.E.R., C.J.B.N.), and Department of Biomedical and Molecular Sciences (J.Y.S., C.J.B.N.), Queen's University, Kingston, Ontario, Canada; National Cancer Institute, National Institutes of Health, Bethesda, Maryland (F.J.G.); and Takeda Pharmaceuticals International, Inc., Cambridge, Massachusetts (J.P.B.)., Zycband EI; Cardiometabolic Disorders Department, Merck Research Laboratories, Kenilworth, New Jersey (T.E.A., L.A.M., N.S., E.I.Z., H.L., J.W.W., C.H.C., J.P.B.); Department of Pathology and Molecular Medicine (G.E.S.-G., E.D.L., C.J.B.N.), Cancer Biology and Genetics Division, Cancer Research Institute (R.E.R., C.J.B.N.), and Department of Biomedical and Molecular Sciences (J.Y.S., C.J.B.N.), Queen's University, Kingston, Ontario, Canada; National Cancer Institute, National Institutes of Health, Bethesda, Maryland (F.J.G.); and Takeda Pharmaceuticals International, Inc., Cambridge, Massachusetts (J.P.B.)., Gonzalez FJ; Cardiometabolic Disorders Department, Merck Research Laboratories, Kenilworth, New Jersey (T.E.A., L.A.M., N.S., E.I.Z., H.L., J.W.W., C.H.C., J.P.B.); Department of Pathology and Molecular Medicine (G.E.S.-G., E.D.L., C.J.B.N.), Cancer Biology and Genetics Division, Cancer Research Institute (R.E.R., C.J.B.N.), and Department of Biomedical and Molecular Sciences (J.Y.S., C.J.B.N.), Queen's University, Kingston, Ontario, Canada; National Cancer Institute, National Institutes of Health, Bethesda, Maryland (F.J.G.); and Takeda Pharmaceuticals International, Inc., Cambridge, Massachusetts (J.P.B.)., Liu H; Cardiometabolic Disorders Department, Merck Research Laboratories, Kenilworth, New Jersey (T.E.A., L.A.M., N.S., E.I.Z., H.L., J.W.W., C.H.C., J.P.B.); Department of Pathology and Molecular Medicine (G.E.S.-G., E.D.L., C.J.B.N.), Cancer Biology and Genetics Division, Cancer Research Institute (R.E.R., C.J.B.N.), and Department of Biomedical and Molecular Sciences (J.Y.S., C.J.B.N.), Queen's University, Kingston, Ontario, Canada; National Cancer Institute, National Institutes of Health, Bethesda, Maryland (F.J.G.); and Takeda Pharmaceuticals International, Inc., Cambridge, Massachusetts (J.P.B.)., Woods JW; Cardiometabolic Disorders Department, Merck Research Laboratories, Kenilworth, New Jersey (T.E.A., L.A.M., N.S., E.I.Z., H.L., J.W.W., C.H.C., J.P.B.); Department of Pathology and Molecular Medicine (G.E.S.-G., E.D.L., C.J.B.N.), Cancer Biology and Genetics Division, Cancer Research Institute (R.E.R., C.J.B.N.), and Department of Biomedical and Molecular Sciences (J.Y.S., C.J.B.N.), Queen's University, Kingston, Ontario, Canada; National Cancer Institute, National Institutes of Health, Bethesda, Maryland (F.J.G.); and Takeda Pharmaceuticals International, Inc., Cambridge, Massachusetts (J.P.B.)., Chang CH; Cardiometabolic Disorders Department, Merck Research Laboratories, Kenilworth, New Jersey (T.E.A., L.A.M., N.S., E.I.Z., H.L., J.W.W., C.H.C., J.P.B.); Department of Pathology and Molecular Medicine (G.E.S.-G., E.D.L., C.J.B.N.), Cancer Biology and Genetics Division, Cancer Research Institute (R.E.R., C.J.B.N.), and Department of Biomedical and Molecular Sciences (J.Y.S., C.J.B.N.), Queen's University, Kingston, Ontario, Canada; National Cancer Institute, National Institutes of Health, Bethesda, Maryland (F.J.G.); and Takeda Pharmaceuticals International, Inc., Cambridge, Massachusetts (J.P.B.)., Berger JP; Cardiometabolic Disorders Department, Merck Research Laboratories, Kenilworth, New Jersey (T.E.A., L.A.M., N.S., E.I.Z., H.L., J.W.W., C.H.C., J.P.B.); Department of Pathology and Molecular Medicine (G.E.S.-G., E.D.L., C.J.B.N.), Cancer Biology and Genetics Division, Cancer Research Institute (R.E.R., C.J.B.N.), and Department of Biomedical and Molecular Sciences (J.Y.S., C.J.B.N.), Queen's University, Kingston, Ontario, Canada; National Cancer Institute, National Institutes of Health, Bethesda, Maryland (F.J.G.); and Takeda Pharmaceuticals International, Inc., Cambridge, Massachusetts (J.P.B.)., Nicol CJB; Cardiometabolic Disorders Department, Merck Research Laboratories, Kenilworth, New Jersey (T.E.A., L.A.M., N.S., E.I.Z., H.L., J.W.W., C.H.C., J.P.B.); Department of Pathology and Molecular Medicine (G.E.S.-G., E.D.L., C.J.B.N.), Cancer Biology and Genetics Division, Cancer Research Institute (R.E.R., C.J.B.N.), and Department of Biomedical and Molecular Sciences (J.Y.S., C.J.B.N.), Queen's University, Kingston, Ontario, Canada; National Cancer Institute, National Institutes of Health, Bethesda, Maryland (F.J.G.); and Takeda Pharmaceuticals International, Inc., Cambridge, Massachusetts (J.P.B.) nicolc@queensu.ca.

Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2019 Mar; Vol. 368 (3), pp. 514-523. Date of Electronic Publication: 2019 Jan 03.